Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- 20 Oct 2023 Status changed from active, no longer recruiting to completed.
- 13 Feb 2023 Planned End Date changed from 30 Sep 2024 to 8 Oct 2023.
- 13 Dec 2022 Planned primary completion date changed from 8 Oct 2022 to 8 Oct 2023.